Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 36

Related Articles by Review for PubMed (Select 21261461)

1.

Contributions of gene marking to cell and gene therapies.

Barese CN, Dunbar CE.

Hum Gene Ther. 2011 Jun;22(6):659-68. doi: 10.1089/hum.2010.237. Epub 2011 May 5. Review.

2.

The continuing contribution of gene marking to cell and gene therapy.

Tey SK, Brenner MK.

Mol Ther. 2007 Apr;15(4):666-76. Epub 2007 Feb 13. Review.

PMID:
17299400
3.

Gene-marking studies of hematopoietic cells.

Bollard CM, Heslop HE, Brenner MK.

Int J Hematol. 2001 Jan;73(1):14-22. Review.

PMID:
11372750
4.

Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.

Persons DA.

Hematology Am Soc Hematol Educ Program. 2009:690-7. doi: 10.1182/asheducation-2009.1.690. Review.

5.

Improved retroviral vectors for hematopoietic stem cell protection and in vivo selection.

Baum C, Eckert HG, Stockschl├Ąder M, Just U, Hegewisch-Becker S, Hildinger M, Uhde A, John J, Ostertag W.

J Hematother. 1996 Aug;5(4):323-9. Review.

PMID:
8877707
6.

Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.

Wu C, Dunbar CE.

Front Med. 2011 Dec;5(4):356-71. doi: 10.1007/s11684-011-0159-1. Epub 2011 Dec 27. Review.

7.

Genotoxicity of retroviral hematopoietic stem cell gene therapy.

Trobridge GD.

Expert Opin Biol Ther. 2011 May;11(5):581-93. doi: 10.1517/14712598.2011.562496. Epub 2011 Mar 7. Review.

8.

Transfer of marker genes into hemopoietic progenitor cells.

Brenner MK, Heslop HE, Rill D, Li C, Smith C, Krance R, Rooney C.

Cytokines Mol Ther. 1996 Sep;2(3):193-200. Review.

PMID:
9384704
9.

Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.

Clay TM, Custer MC, Spiess PJ, Nishimura MI.

Pathol Oncol Res. 1999;5(1):3-15. Review.

10.

Gene therapy using hematopoietic stem cells: Sisyphus approaches the crest.

Halene S, Kohn DB.

Hum Gene Ther. 2000 Jun 10;11(9):1259-67. Review.

PMID:
10890736
11.

Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.

Brentjens RJ, Curran KJ.

Hematology Am Soc Hematol Educ Program. 2012;2012:143-51. doi: 10.1182/asheducation-2012.1.143. Review.

12.

Use of gene marking technologies in oncology.

Brenner M.

Forum (Genova). 1998 Oct-Dec;8(4):342-53. Review.

PMID:
9863029
13.

The contribution of marker gene studies to hemopoietic stem cell therapies.

Brenner MK.

Stem Cells. 1995 Sep;13(5):453-61. Review.

PMID:
8528094
14.

Genetic manipulation of hematopoietic stem cells.

Larochelle A, Dunbar CE.

Semin Hematol. 2004 Oct;41(4):257-71. Review.

PMID:
15508111
15.

Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.

Talmadge JE.

Int Immunopharmacol. 2003 Aug;3(8):1121-43. Review.

PMID:
12860168
16.

Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors.

Haviernik P, Bunting KD.

Curr Gene Ther. 2004 Sep;4(3):263-76. Review.

PMID:
15384940
17.

Survival of the fittest: in vivo selection and stem cell gene therapy.

Neff T, Beard BC, Kiem HP.

Blood. 2006 Mar 1;107(5):1751-60. Epub 2005 Nov 3. Review.

18.

Non-myeloablative transplants for malignant disease.

Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH.

Hematology Am Soc Hematol Educ Program. 2001:375-91. Review.

19.

Genetically marking human cells--results of the first clinical gene transfer studies.

Cai Q, Rubin JT, Lotze MT.

Cancer Gene Ther. 1995 Jun;2(2):125-36. Review.

PMID:
7621260
20.

Gene marking.

Brenner M.

Hum Gene Ther. 1996 Oct 20;7(16):1927-36. Review.

PMID:
8930652
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk